Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (“crPhage\u2122”) products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n\n\n\n
Under the terms of the agreement, Locus will receive $20 million<\/span> in initial payments, and is eligible to receive up to a total of $798 million<\/span> in potential future development and commercial milestone payments, and royalties on any product sales.<\/p>\n\n\nRead More<\/span>\n\t\t<\/use>\n<\/svg>\n<\/span><\/a><\/div>\n\n<\/div>\n\n","protected":false,"raw":"\n\n\n\n\nLocus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (\"crPhage\u2122\") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n\n\n\nUnder the terms of the agreement, Locus will receive $20 million<\/span> in initial payments, and is eligible to receive up to a total of $798 million<\/span> in potential future development and commercial milestone payments, and royalties on any product sales.<\/p>\n\n\n\n\nRead More<\/span>\n<\/svg>\n<\/span><\/a><\/div>\n<\/div>\n"},"excerpt":{"rendered":"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (“crPhage\u2122”) products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n","protected":false},"author":239,"featured_media":15171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[],"_ncst_magazine_issue":[],"class_list":["post-10987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\nLocus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage\u2122") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-03T19:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T00:42:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics\",\"datePublished\":\"2019-01-03T19:22:10+00:00\",\"dateModified\":\"2023-11-21T00:42:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"},\"wordCount\":138,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\",\"name\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"datePublished\":\"2019-01-03T19:22:10+00:00\",\"dateModified\":\"2023-11-21T00:42:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"width\":1601,\"height\":900,\"caption\":\"Brand logo for \\\"LOCUS BIOSCIENCES\\\" featuring a red and grey DNA helix icon next to text reading \\\"ENGINEERING PRECISION MEDICINES,\\\" superimposed over a dark background with a glowing, red particle-style DNA double helix.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","og_description":"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (\"crPhage\u2122\") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","og_site_name":"Office of Research Commercialization","article_published_time":"2019-01-03T19:22:10+00:00","article_modified_time":"2023-11-21T00:42:57+00:00","og_image":[{"width":1601,"height":900,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics","datePublished":"2019-01-03T19:22:10+00:00","dateModified":"2023-11-21T00:42:57+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"},"wordCount":138,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","name":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","datePublished":"2019-01-03T19:22:10+00:00","dateModified":"2023-11-21T00:42:57+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","width":1601,"height":900,"caption":"Brand logo for \"LOCUS BIOSCIENCES\" featuring a red and grey DNA helix icon next to text reading \"ENGINEERING PRECISION MEDICINES,\" superimposed over a dark background with a glowing, red particle-style DNA double helix."},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=10987"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987\/revisions"}],"predecessor-version":[{"id":15173,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987\/revisions\/15173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/15171"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=10987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=10987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=10987"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=10987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (\"crPhage\u2122\") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n\n\n\n
Under the terms of the agreement, Locus will receive $20 million<\/span> in initial payments, and is eligible to receive up to a total of $798 million<\/span> in potential future development and commercial milestone payments, and royalties on any product sales.<\/p>\n\n\n\n\nRead More<\/span>\n<\/svg>\n<\/span><\/a><\/div>\n<\/div>\n"},"excerpt":{"rendered":"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (“crPhage\u2122”) products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n","protected":false},"author":239,"featured_media":15171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[],"_ncst_magazine_issue":[],"class_list":["post-10987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\nLocus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage\u2122") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-03T19:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T00:42:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics\",\"datePublished\":\"2019-01-03T19:22:10+00:00\",\"dateModified\":\"2023-11-21T00:42:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"},\"wordCount\":138,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\",\"name\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"datePublished\":\"2019-01-03T19:22:10+00:00\",\"dateModified\":\"2023-11-21T00:42:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2019\\\/02\\\/ORC-news-photo-.png\",\"width\":1601,\"height\":900,\"caption\":\"Brand logo for \\\"LOCUS BIOSCIENCES\\\" featuring a red and grey DNA helix icon next to text reading \\\"ENGINEERING PRECISION MEDICINES,\\\" superimposed over a dark background with a glowing, red particle-style DNA double helix.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2019\\\/01\\\/03\\\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","og_description":"Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (\"crPhage\u2122\") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","og_site_name":"Office of Research Commercialization","article_published_time":"2019-01-03T19:22:10+00:00","article_modified_time":"2023-11-21T00:42:57+00:00","og_image":[{"width":1601,"height":900,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics","datePublished":"2019-01-03T19:22:10+00:00","dateModified":"2023-11-21T00:42:57+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"},"wordCount":138,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/","name":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","datePublished":"2019-01-03T19:22:10+00:00","dateModified":"2023-11-21T00:42:57+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","width":1601,"height":900,"caption":"Brand logo for \"LOCUS BIOSCIENCES\" featuring a red and grey DNA helix icon next to text reading \"ENGINEERING PRECISION MEDICINES,\" superimposed over a dark background with a glowing, red particle-style DNA double helix."},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2019\/01\/03\/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=10987"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987\/revisions"}],"predecessor-version":[{"id":15173,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10987\/revisions\/15173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/15171"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=10987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=10987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=10987"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=10987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage (“crPhage\u2122”) products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. \u00a0Johnson & Johnson Innovation LLC facilitated the transaction.<\/p>\n","protected":false},"author":239,"featured_media":15171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[],"_ncst_magazine_issue":[],"class_list":["post-10987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\n